Scabies community prevalence and mass drug administration in two Fijian villages

International Journal of Dermatology

Volumn 53, Issue 6, 2014, Pages 739-745

  Haar, Karin ^a,g   Romani, Lucia ^b   Filimone, Raikanikoda ^c   Kishore, Kamal ^d   Tuicakau, Meciusela ^c   Koroivueta, Josefa ^c   Kaldor, John M ^b   Wand, Handan ^b   Steer, Andrew ^e   Whitfeld, Margot ^f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Ministry of Health   (Fiji)

^d FIJI NATIONAL UNIVERSITY   (Fiji)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL BENZOATE; FLUOCINONIDE; IVERMECTIN; PERMETHRIN; BENZOIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FIJI; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SCABIES; SINGLE DRUG DOSE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BENZOATES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DEVELOPING COUNTRIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIJI; FOLLOW-UP STUDIES; HUMANS; IVERMECTIN; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; SCABIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900791681     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12353     Document Type: Article

References (25)

1. Chosidow O. Scabies. N Engl J Med 2006; 354: 1718-1727.
2. Svartman M, Finklea JF, Earle DP, et al. Epidemic scabies and acute glomerulonephritis in Trinidad. Lancet 1972; 1: 249-251.
3. Heukelbach J, Feldmeier H. Scabies. Lancet 2006; 367: 1767-1774.
4. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis 2012; 25: 145-153.
5. WHO. Epidemiology and Management of Common Skin Diseases in Children in Developing Countries. Geneva: World Health Organisation, 2005.
6. Steer AC, Jenney AWJ, Kado J, et al. High burden of impetigo and scabies in a tropical country. PLoS Negl Trop Dis 2009; 87: 173-179.
7. Steer AC, Tikoduadua LV, Manalac EM, et al. Validation of an integrated management of childhood illness algorithm for managing common skin conditions in Fiji. Bull World Health Organ 2009b; 87: 173-179.
8. Leppard B, Naburi AE. The use of ivermectin in controlling an outbreak of scabies in a prison. Br J Dermatol 2000; 143: 520-523.
9. Meinking TL, Taplin D, Hermida JL, et al. The treatment of scabies with ivermectin. N Engl J Med 1995; 333: 26-30.
10. Sullivan JR, Watt G, Barker B. Successful use of ivermectin in the treatment of endemic scabies in a nursing home. Australas J Dermatol 1997; 38: 137-140.
11. Paasch U, Haustein UF. Management of endemic outbreaks of scabies with allethrin, permethrin, and ivermectin. Int J Dermatol 2000; 39: 463-470.
12. Abedin S, Narang M, Gandhi V, et al. Efficacy of permethrin cream and oral ivermectin in treatment of scabies. Indian J Pediatr 2007; 74: 915-916.
13. Jimenez-Lucho VE, Fallon F, Caputo C, et al. Role of prolonged surveillance in the eradication of nosocomial scabies in an extended care Veterans Affairs medical center. Am J Infect Control 1995; 23: 44-49.
14. Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health 2002; 38: 401-404.
15. Elmogy M, Fayed H, Marzok H, et al. Oral ivermectin in the treatment of scabies. Int J Dermatol 1999; 38: 926-928.
16. Dourmishev A, Serafimova D, Dourmishev L. Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol 1998; 11: 247-251.
17. Chouela EN, Abeldano AM, Pellerano G, et al. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol 1999; 135: 651-655.
18. Steer A, Jenney AJW, Oppedisano F, et al. High burden of invasive β-haemolytic streptococcal infections in Fiji. Epidemiol Infect 2008; 136: 621-627.
19. Heukelbach J, Wilcke T, Winter B, et al. Epidemiology and morbidity of scabies and pediculosis capitis in resource-poor communities in Brazil. Br J Dermatol 2005; 153: 150-156.
20. dos Santos MML, Amaral S, Harmen SP, et al. The prevalence of common skin infections in four districts in Timor-Leste: a cross sectional survey. BMC Infect Dis 2009; 10: 61.
21. Lawrence G, Leafasia J, Sheridan J, et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Organ 2005; 83: 34-42.
22. Harris M, Nako D, Hopkins T, et al. Skin infections in Tanna, Vanuatu in 1989. P N G Med J 1992; 35: 137-143.
23. Schmeller W, Dzikus A. Skin diseases in children in rural Kenya: long-term results of a dermatology project within the primary health care system. Br J Dermatol 2001; 144: 118-124.
24. Bockarie MJ, Alexander NDE, Kazura JW, et al. Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. Acta Trop 2000; 75: 127-130.
25. Taplin D, Porcelain SL, Meinking TL, et al. Community control of scabies: a model based on use of permethrin cream. Lancet 1991; 337: 1016-1018.